[Objective]To compare the efficacy of olsalazine vs salazosulfapyridine(SASP) for the treatment of ulcerative colitis. [Methods] Totally 82 patients with ulcerative colitis in our hospital were selected and randomly divided into observation group and control group with 41 cases in each group. The control group was given SASP lg per time for 4 times daily. The observation group was given olsalazine lg per time for 3 times daily. The treatment course was 8 weeks. The clinical efficacy, the change of serum inflammatory factors and adverse reaction were compared between two groups. [Results]The total effective rate of observation group was obviously higher than that of control group(97. 56% vs 70. 73%). The incidence of adverse reaction in observation group was obviously lower than that in control group(2. 44% vs 34. 15%). There were significant differences(all P <0. 05). The decreased levels of TNF-α, IL-6 and IL-8 in serum of observation group after treatment were significantly higher than those of control group( P <0. 05). [Conclusion]Olsalazine for the treatment of ulcerative colitis has certain efficacy with less adverse reaction, so it is worthy of clinical application.%[目的]比较奥沙拉嗪与柳氮磺胺嘧啶(SASP)治疗溃疡性结肠炎的临床疗效.[方法]选取在本院治疗的溃疡性结肠炎患者82例,随机分为观察组和对照组,每组41例.对照组给予SASP,每次1 g,每日4次; 观察组给予奥沙拉嗪,每次1 g,每日3次 进行治疗,疗程8周,比较两组临床疗效和血清炎性因子的变化及不良反应.[结果]观察组总有效率明显高于对照组(97.56% vs 70.73%),不良反应发生率明显低于对照组(2.44% vs 34.15%),差异均有显著性(均P<0.05).且观察组治疗后血清肿瘤坏死因子-α、白介素-6和白介素-8水平的降低幅度明显高于对照组(P<0.05).[结论]奥沙拉嗪治疗溃疡性结肠炎效果确切,不良反应少,值得临床推广应用.
展开▼
